AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27343417 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin therapy
Number of subjects: 407
Study 25465416 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 26449
Study 25465416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26449
Study 22441756 — intervention group
Group type: EXPERIMENTAL
Intervention: Third Eye Retroscope (TER)
Number of subjects: 406
Study 22441756 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 406
Study 22441756 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 406
Study 22441756 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenomas in the left colon
Number of subjects: 406
Study 20451694 — intervention group
Group type: COMPARATOR
Intervention: Normal BMI (18.5 to 24.9 kg/m²)
Number of subjects: 1703
Study 20451694 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight (BMI 25.0 to 29.9 kg/m²)
Number of subjects: 1703
Study 20451694 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese (BMI ≥30.0 kg/m²)
Number of subjects: 1703
Study 20451694 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 1703
Study 18217149 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/day clopidogrel
Number of subjects: 40
Study 18217149 — intervention group
Group type: COMPARATOR
Intervention: 75 mg/day clopidogrel
Number of subjects: 40
Study 15713204 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresnel prisms
Number of subjects: 0
Study 15713204 — intervention group
Group type: COMPARATOR
Intervention: Gottlieb Visual Field Awareness System
Number of subjects: 0
Study 12799117 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil formulation dentifrice
Number of subjects: 20
Study 12799117 — intervention group
Group type: COMPARATOR
Intervention: Fluoride‐matched control
Number of subjects: 20
Study 11102258 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 0
Study 8795167 — intervention group
Group type: EXPERIMENTAL
Intervention: Original readings of carotid IMT measurements at baseline
Number of subjects: 919
Study 8795167 — intervention group
Group type: EXPERIMENTAL
Intervention: Original readings of carotid IMT measurements at 36 months
Number of subjects: 919
Study 8795167 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-year change in carotid IMT measurements
Number of subjects: 919
Study 8795167 — intervention group
Group type: COMPARATOR
Intervention: Rereadings of carotid IMT measurements
Number of subjects: 919
Study 8795167 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraclass correlation coefficients between original readings and rereadings
Number of subjects: 919
Study 1735697 — intervention group
Group type: EXPERIMENTAL
Intervention: AK-2123 (3-nitro-1,2,4-triazole) intratumoral injection at 1% and 2%
Number of subjects: 80
Study 1735697 — intervention group
Group type: EXPERIMENTAL
Intervention: AK-2123 (3-nitro-1,2,4-triazole) intratumoral injection
Number of subjects: 80
Study 6365350 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg orally every 4 hr for 14 days)
Number of subjects: 171
Study 6365350 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus standard care
Number of subjects: 171
Study 6365350 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 171
Study 6365350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 31473065 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention delivered by community health workers with tailored text messages for 18 months
Number of subjects: 1954
Study 31473065 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1954
Study 31473065 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 1954
Study 30103622 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer (8.4 g/d to start, adjusted to maintain serum potassium of 3.8 to 5.0 mEq/L)
Number of subjects: 112
Study 26987723 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 6
Study 26987723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 23915056 — intervention group
Group type: EXPERIMENTAL
Intervention: ITC representation of objects
Number of subjects: 0
Study 23915056 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit behavioral ratings of semantic similarity
Number of subjects: 0
Study 23915056 — intervention group
Group type: EXPERIMENTAL
Intervention: Computational measures of semantic similarity
Number of subjects: 0
Study 23915056 — intervention group
Group type: COMPARATOR
Intervention: Earlier visual areas (V1)
Number of subjects: 0
Study 22402220 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised resistance training
Number of subjects: 15
Study 22402220 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 15
Study 20210620 — intervention group
Group type: EXPERIMENTAL
Intervention: PC17 jacket
Number of subjects: 12
Study 20210620 — intervention group
Group type: EXPERIMENTAL
Intervention: gel jacket
Number of subjects: 12
Study 20210620 — intervention group
Group type: COMPARATOR
Intervention: no jacket (control)
Number of subjects: 12
Study 18538692 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-NB treatment
Number of subjects: 48
Study 18538692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 16006454 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/day acarbose
Number of subjects: 30
Study 16006454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10049281 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine (40 mg twice daily) in combination with one to three other drugs for opportunistic infections
Number of subjects: 10
Study 10049281 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine (40 mg twice daily)
Number of subjects: 10
Study 8657058 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg on the first day, then 100 mg daily for 13 days)
Number of subjects: 30
Study 8657058 — intervention group
Group type: COMPARATOR
Intervention: Control group (same parodontal therapy without doxycycline)
Number of subjects: 30
Study 2189989 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftifine cream 1%
Number of subjects: 57
Study 2189989 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole cream 1%
Number of subjects: 57
Study 348309 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (CY), 60 mg/kg iv, given on Days 1 and 2
Number of subjects: 23
Study 348309 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (CY), 60 mg/kg iv, given on Days 1 and 8
Number of subjects: 23
Study 348309 — intervention group
Group type: EXPERIMENTAL
Intervention: COMB (CY, 800 mg/m2; vincristine [Oncovin], 1.4 mg/m2; methotrexate, 20 mg/m2; and BCNU, 60 mg/m2)
Number of subjects: 23
Study 31331099 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (WHEY)
Number of subjects: 22
Study 31331099 — intervention group
Group type: COMPARATOR
Intervention: Nonessential amino acids blend (NEAA)
Number of subjects: 22
Study 28583057 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure at shen men, point zero, and subcortex points
Number of subjects: 0
Study 28583057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28583057 — intervention group
Group type: COMPARATOR
Intervention: Sham acupressure
Number of subjects: 0
Study 26252777 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (LSI) plus Berberine (BBR) 0.5g tid for 16 weeks
Number of subjects: 184
Study 26252777 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle intervention (LSI)
Number of subjects: 184
Study 24146421 — intervention group
Group type: EXPERIMENTAL
Intervention: Mydriasert (conjunctival insert)
Number of subjects: 10
Study 24146421 — intervention group
Group type: COMPARATOR
Intervention: Tropicamide/phenylephrine eye drops
Number of subjects: 10
Study 24146421 — intervention group
Group type: COMPARATOR
Intervention: Atropine
Number of subjects: 10
Study 20970517 — intervention group
Group type: EXPERIMENTAL
Intervention: BD+ICS
Number of subjects: 22
Study 20970517 — intervention group
Group type: COMPARATOR
Intervention: PL
Number of subjects: 22
Study 17376722 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI 80/4.5 microg
Number of subjects: 622
Study 17376722 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol DPI 80/4.5 microg
Number of subjects: 622
Study 17376722 — intervention group
Group type: COMPARATOR
Intervention: Budesonide pMDI 100 microg
Number of subjects: 622
Study 16615717 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample nonwords presented in groups with the same word rules
Number of subjects: 0
Study 16615717 — intervention group
Group type: EXPERIMENTAL
Intervention: Grouping of word exemplars by category
Number of subjects: 0
Study 16615717 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthographic characteristics of words
Number of subjects: 0
Study 12898557 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorexia Nervosa (AN)
Number of subjects: 98
Study 12898557 — intervention group
Group type: COMPARATOR
Intervention: Major Depressive Disorder (MDD)
Number of subjects: 98
Study 12898557 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorexia Nervosa (AN) subtypes
Number of subjects: 98
Study 11107508 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary administration of dipyridamole (0.5 mg/kg body weight)
Number of subjects: 30
Study 11107508 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 30
Study 9236429 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of Ang II
Number of subjects: 8
Study 9236429 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 8
Study 8026410 — intervention group
Group type: EXPERIMENTAL
Intervention: High VNS
Number of subjects: 67
Study 8026410 — intervention group
Group type: COMPARATOR
Intervention: Low VNS to High VNS
Number of subjects: 67
Study 2690334 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily
Number of subjects: 164
Study 2690334 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg daily
Number of subjects: 164
Study 2690334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 2690334 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 164
Study 970899 — intervention group
Group type: EXPERIMENTAL
Intervention: Althesin
Number of subjects: 60
Study 970899 — intervention group
Group type: COMPARATOR
Intervention: methohexitone
Number of subjects: 60
Study 31201202 — intervention group
Group type: EXPERIMENTAL
Intervention: eCARE programme (SMS support)
Number of subjects: 424
Study 31201202 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 424
Study 29485790 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol administered through patient-controlled analgesia (PCA) pump
Number of subjects: 0
Study 29485790 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol administered intermittently
Number of subjects: 0
Study 25344090 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg AA
Number of subjects: 30
Study 25344090 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg AA
Number of subjects: 30
Study 25344090 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg AA
Number of subjects: 30
Study 25344090 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 hour premeal 1000 mg AA
Number of subjects: 30
Study 25344090 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 hours postmeal 1000 mg AA
Number of subjects: 30
Study 25344090 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 hours apart meals 1000 mg AA
Number of subjects: 30
Study 23497514 — intervention group
Group type: EXPERIMENTAL
Intervention: A/A genotype at age 4
Number of subjects: 963
Study 23497514 — intervention group
Group type: EXPERIMENTAL
Intervention: A/A genotype at age 8
Number of subjects: 963
Study 23497514 — intervention group
Group type: EXPERIMENTAL
Intervention: At least one copy of the A allele in schoolchildren sample
Number of subjects: 963
Study 21806789 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-week high intensity progressive resistance training (HIPRT) program
Number of subjects: 30
Study 21806789 — intervention group
Group type: COMPARATOR
Intervention: Standard care (UNT)
Number of subjects: 30
Study 21806789 — intervention group
Group type: COMPARATOR
Intervention: Healthy matched control subjects (CON) completing the same HIPRT program
Number of subjects: 30
Study 19144392 — intervention group
Group type: EXPERIMENTAL
Intervention: NovaSil clay (high dose)
Number of subjects: 177
Study 19144392 — intervention group
Group type: EXPERIMENTAL
Intervention: NovaSil clay (low dose)
Number of subjects: 177
Study 19144392 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 177
Study 18174931 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled sideline environment
Number of subjects: 21
Study 18174931 — intervention group
Group type: COMPARATOR
Intervention: Controlled locker room environment
Number of subjects: 21
Study 14709460 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous three‐in‐one femoral nerve block (FEM) with 30 mL ropivacaine 0.5% and epinephrine 1:200,000 bolus followed by an infusion of ropivacaine 0.2% at 12 mL/hr for 48 hr
Number of subjects: 60
Study 14709460 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous posterior lumbar plexus (PSOAS) block with the same bolus and infusion regimen as the FEM group
Number of subjects: 60
Study 14709460 — intervention group
Group type: COMPARATOR
Intervention: iv patient‐controlled morphine analgesia (PCA)
Number of subjects: 60
Study 11826911 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine syrup 5 mg or 10 mg daily for 3 weeks
Number of subjects: 60
Study 11826911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8956350 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic methadone (n = 13)
Number of subjects: 26
Study 8956350 — intervention group
Group type: COMPARATOR
Intervention: l-methadone (n = 13)
Number of subjects: 26
Study 14621848 — intervention group
Group type: EXPERIMENTAL
Intervention: CyG
Number of subjects: 10
Study 14621848 — intervention group
Group type: COMPARATOR
Intervention: CyA
Number of subjects: 10
Study 3887391 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (Cys) and prednisone
Number of subjects: 43
Study 3887391 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (Aza) and prednisone
Number of subjects: 43
Study 31086287 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg rhCC10
Number of subjects: 88
Study 31086287 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg rhCC10
Number of subjects: 88
Study 31086287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 29972633 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 10 mg with Cyclosporine 100 mg
Number of subjects: 12
Study 29972633 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 10 mg with Tacrolimus 5 mg
Number of subjects: 12
Study 26760084 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified treatment (higher-dose rifampin 15 mg/kg/day and levofloxacin 20 mg/kg/day for the first 8 weeks)
Number of subjects: 817
Study 26760084 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen (10 mg rifampin/kg/day for 9 months)
Number of subjects: 817
Study 26760084 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified treatment
Number of subjects: 817
Study 26760084 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 817
Study 24694949 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality and Outcomes Framework (QOF) pay-for-performance program
Number of subjects: 110000
Study 22554203 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin-naphthoquine (AN) - single dose of four tablets on day 0
Number of subjects: 401
Study 22554203 — intervention group
Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DHP) - three to four tablets daily for three days
Number of subjects: 401
Study 19088171 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib 100 mg + pemetrexed (500 mg/m2 i.v. every 21 days)
Number of subjects: 21
Study 19088171 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg + pemetrexed (500 mg/m2 i.v. every 21 days)
Number of subjects: 21
Study 19088171 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib 100 mg + pemetrexed
Number of subjects: 21
Study 19088171 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg + pemetrexed
Number of subjects: 21
Study 17625917 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg)
Number of subjects: 24
Study 17625917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 16449845 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid
Number of subjects: 83
Study 16449845 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 83
Study 16449845 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Nicotinic acid and Bezafibrate
Number of subjects: 83
Study 12133363 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) in group B(1), n = 20
Number of subjects: 60
Study 12133363 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B(2), n = 20)
Number of subjects: 60
Study 12133363 — intervention group
Group type: COMPARATOR
Intervention: No intervention (group A, n = 20)
Number of subjects: 60
Study 12133363 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups post-CPB
Number of subjects: 60
Study 9818786 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg picotamide daily
Number of subjects: 50
Study 9818786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 7714936 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorinated water
Number of subjects: 171
Study 7714936 — intervention group
Group type: COMPARATOR
Intervention: Non-chlorinated water
Number of subjects: 171
Study 2189867 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone hydrochloride (Trexan)
Number of subjects: 1
Study 2189867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 35211 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam 20 mg
Number of subjects: 0
Study 35211 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam 10 mg three times daily
Number of subjects: 0
Study 35211 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 0
Study 35211 — intervention group
Group type: COMPARATOR
Intervention: Amylobarbitone sodium 100 mg
Number of subjects: 0
Study 35211 — intervention group
Group type: COMPARATOR
Intervention: Nitrazepam 5 mg
Number of subjects: 0
Study 35211 — intervention group
Group type: COMPARATOR
Intervention: Chlordiazepoxide 10 mg three times daily
Number of subjects: 0
Study 35211 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 5 mg three times daily
Number of subjects: 0
Study 35211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28403662 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum amyloid A (SAA)
Number of subjects: 35
Study 28403662 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble intercellular adhesion molecule 1 (sICAM‐1)
Number of subjects: 35
Study 28403662 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pulmonary infection score (CPIS)
Number of subjects: 35
Study 28403662 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CPIS and SAA
Number of subjects: 35
Study 28403662 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 35
Study 27632342 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel spacer injection before RT
Number of subjects: 167
Study 26402319 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination sedation (repeated bolus doses of fentanyl with propofol infusion)
Number of subjects: 202
Study 26402319 — intervention group
Group type: COMPARATOR
Intervention: Conventional sedation (initial bolus of meperidine with propofol infusion)
Number of subjects: 202
Study 26402319 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination sedation
Number of subjects: 202
Study 26402319 — intervention group
Group type: COMPARATOR
Intervention: Conventional sedation
Number of subjects: 202
Study 23867129 — intervention group
Group type: EXPERIMENTAL
Intervention: ARCON (Accelerated Radiotherapy combined with carbogen and nicotinamide)
Number of subjects: 272
Study 23867129 — intervention group
Group type: COMPARATOR
Intervention: AR (Accelerated Radiotherapy)
Number of subjects: 272
Study 21899733 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-nutrient supplement
Number of subjects: 31
Study 19473534 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentor mother support for up to 12 months
Number of subjects: 0
Study 19473534 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 17206293 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of prostate (TURP)
Number of subjects: 87
Study 17206293 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-contact laser prostatectomy using ND: YAG laser at 40‐60 watt power and 13000‐29000 joules energy settings
Number of subjects: 87
Study 15497670 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (30 mg pioglitazone hydrochloride)
Number of subjects: 26
Study 15497670 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (30 mg pioglitazone hydrochloride)
Number of subjects: 26
Study 15497670 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation and Reference formulation
Number of subjects: 26
Study 11928567 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled heparin
Number of subjects: 15
Study 11928567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9466097 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections pre- and intra-operatively (Group A)
Number of subjects: 137
Study 9466097 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo pre-operatively and ketorolac 30 mg intra-operatively (Group B)
Number of subjects: 137